|
| 37365802 | Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinic. | | 2023 |
| 36896821 | Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting. | | 2023 |
| 37200995 | Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. | EClinicalMedicine | 2023 |
| 35350172 | Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study. | Open Forum Infectious Diseases | 2022 |
| 35502922 | Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHTE Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1. | Antimicrobial Agents and Chemotherapy | 2022 |
| 35551291 | Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. | Nature Medicine | 2022 |
| 35544387 | Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. | New England Journal of Medicine | 2022 |
| 34587382 | Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. | N Engl J Med | 2021 |
| 34162752 | The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. | Sci Transl Med | 2021 |
| 34000227 | Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial. | Lancet HIV,The | 2021 |
| 33941212 | Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV. | AIDS Research and Therapy | 2021 |
| 33262130 | Determinants of pre-exposure prophylaxis (PrEP) persistence in a high-risk population in Central Florida. | Journal of Investigative Medicine | 2021 |
| 33043969 | Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1. | Clinical Infectious Diseases | 2021 |
| 34621054 | Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. | Nature Medicine | 2021 |
| 34559154 | Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV. | Medicine (Baltimore) | 2021 |
| 31121015 | Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis. | Clinical Infectious Diseases | 2020 |
| 31740348 | Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. | Lancet HIV,The | 2020 |
| 31769793 | A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection. | Clinical Infectious Diseases | 2020 |
| 32212519 | Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. | New England Journal of Medicine | 2020 |
| 32711800 | Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. | Lancet, The | 2020 |
| 32698728 | Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatment. | International Journal of STD and AIDS | 2020 |
| 32504574 | Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. | Lancet HIV | 2020 |
| 33329900 | Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world setting. | Journal of Virus Eradication | 2020 |
| 31425317 | Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations. | Journal of acquired immune deficiency syndromes (1999) | 2019 |
| 31609930 | Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial. | Journal of acquired immune deficiency syndromes (1999) | 2019 |
| 31464642 | Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study. | AIDS Research and Therapy | 2019 |
| 31434737 | Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial. | J Virol | 2019 |
| 30997864 | Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults. | Pulmonary Circulation | 2019 |
| 29794828 | Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide. | AIDS | 2018 |
| 28799919 | Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA â¿¥1,000,000 copies/ml: a post hoc analysis of Phase III clinical trials. | Antivir Ther | 2018 |
| 29925490 | Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, ph | Lancet HIV,The | 2018 |
| 30101539 | Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. | HIV Medicine | 2018 |
| 30319119 | Antiretroviral switch studies do matter. | Lancet HIV,The | 2018 |
| 29475804 | Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. | Lancet HIV | 2018 |
| 29368537 | Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. | AIDS Research and Human Retroviruses | 2018 |
| 29592840 | Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. | Lancet HIV,The | 2018 |
| 29325070 | Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. | J Infect Dis | 2018 |
| 28259776 | Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-i | Lancet HIV,The | 2017 |
| 28867499 | Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiori | Lancet, The | 2017 |
| 28555519 | Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. | HIV Clin Trials | 2017 |
| 28577353 | Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study. | BMC Infectious Diseases | 2017 |
| 28282300 | Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. | J Acquir Immune Defic Syndr | 2017 |
| 28219610 | Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. | Lancet HIV,The | 2017 |
| 28196003 | Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1-Infected Adults. | Journal of acquired immune deficiency syndromes (1999) | 2017 |
| 27587070 | Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice. | Clinical Drug Investigation | 2017 |
| 28259777 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. | Lancet HIV,The | 2017 |
| 27704731 | Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Asian Subjects with Human Immunodeficiency Virus 1 Infection: A Sub-Analysis of Phase 3 Clinical Trials. | Infection and Chemotherapy | 2016 |
| 26871794 | The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial. | Medicine (Baltimore) | 2016 |
| 27036991 | Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, activ | Lancet HIV,The | 2016 |
| 26176344 | The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudineâ¿¿+â¿¿atazanavir. | HIV Med | 2016 |